CA2316364A1 - Methode pour le pronostic de maladie, par l'etablissement du genotype du recepteur fc - Google Patents

Methode pour le pronostic de maladie, par l'etablissement du genotype du recepteur fc Download PDF

Info

Publication number
CA2316364A1
CA2316364A1 CA002316364A CA2316364A CA2316364A1 CA 2316364 A1 CA2316364 A1 CA 2316364A1 CA 002316364 A CA002316364 A CA 002316364A CA 2316364 A CA2316364 A CA 2316364A CA 2316364 A1 CA2316364 A1 CA 2316364A1
Authority
CA
Canada
Prior art keywords
disease
benign
prognosis
genotype
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002316364A
Other languages
English (en)
Inventor
Kjell-Morten Myhr
Christian Alexander Vedeler
Harold Inge Nyland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIFOB Universitetsforskning Bergen (Bergen Univ Res Foundation)
Original Assignee
Kjell-Morten Myhr
Christian Alexander Vedeler
Stiftelsen Universitetsforskning Bergen (Unifob)
Harold Inge Nyland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9727055.7A external-priority patent/GB9727055D0/en
Priority claimed from GBGB9802207.2A external-priority patent/GB9802207D0/en
Application filed by Kjell-Morten Myhr, Christian Alexander Vedeler, Stiftelsen Universitetsforskning Bergen (Unifob), Harold Inge Nyland filed Critical Kjell-Morten Myhr
Publication of CA2316364A1 publication Critical patent/CA2316364A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
CA002316364A 1997-12-22 1998-12-22 Methode pour le pronostic de maladie, par l'etablissement du genotype du recepteur fc Abandoned CA2316364A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9727055.7A GB9727055D0 (en) 1997-12-22 1997-12-22 Method
GB9727055.7 1997-12-22
GB9802207.2 1998-02-02
GBGB9802207.2A GB9802207D0 (en) 1998-02-02 1998-02-02 Method
PCT/GB1998/003872 WO1999032659A1 (fr) 1997-12-22 1998-12-22 Methode pour le pronostic de maladie, par l'etablissement du genotype du recepteur fc

Publications (1)

Publication Number Publication Date
CA2316364A1 true CA2316364A1 (fr) 1999-07-01

Family

ID=26312824

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002316364A Abandoned CA2316364A1 (fr) 1997-12-22 1998-12-22 Methode pour le pronostic de maladie, par l'etablissement du genotype du recepteur fc

Country Status (7)

Country Link
US (1) US20040235045A1 (fr)
EP (1) EP1042505A1 (fr)
AU (1) AU764006B2 (fr)
CA (1) CA2316364A1 (fr)
NO (1) NO20003212L (fr)
NZ (1) NZ505710A (fr)
WO (1) WO1999032659A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103765D0 (en) * 2001-02-15 2001-04-04 Affitech As Assay
AU2002253568A1 (en) * 2002-04-24 2003-11-10 Wako Pure Chemical Industries, Ltd. Method of judging the onset risk of arteriosclerosis and arteriosclerotic complication
GB0324778D0 (en) * 2003-10-23 2003-11-26 Forinnova As Method
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
US20090062162A1 (en) * 2007-08-28 2009-03-05 Chevron U.S.A. Inc. Gear oil composition, methods of making and using thereof
WO2010094525A1 (fr) * 2009-01-16 2010-08-26 Merck Serono S.A. Marqueurs génétiques pour le diagnostic de formes progressives primaires de la sclérose en plaques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016628A1 (fr) * 1990-04-24 1991-10-31 The Regents Of The University Of California Purification, detection et procedes d'utilisation de protease nexine-2
EP0714409A1 (fr) * 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
WO1995005481A1 (fr) * 1993-08-18 1995-02-23 Isis Innovation Limited Procede de diagnostic et therapie
IL113484A0 (en) * 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
US5830652A (en) * 1994-08-30 1998-11-03 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for determining predisposition to severe forms of autoimmune disease by determining Fcy receptor allelic patterns
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
GB9517585D0 (en) * 1995-08-29 1995-11-01 Cookson William O C Atopy diagnosis and therapy
US5985561A (en) * 1996-06-03 1999-11-16 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery FC receptor polymorphism

Also Published As

Publication number Publication date
NZ505710A (en) 2003-03-28
EP1042505A1 (fr) 2000-10-11
NO20003212L (no) 2000-08-10
WO1999032659A1 (fr) 1999-07-01
US20040235045A1 (en) 2004-11-25
AU1772999A (en) 1999-07-12
AU764006B2 (en) 2003-08-07
NO20003212D0 (no) 2000-06-21

Similar Documents

Publication Publication Date Title
Reveille The genetic contribution to the pathogenesis of rheumatoid arthritis
Mansfield et al. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes
Gough et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome
Jefferson et al. Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes (COL4A3 and COL4A4).
Dijstelbloem et al. Fcγ receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse
Brown Genetics and the pathogenesis of ankylosing spondylitis
van Sorge et al. Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms
Callea et al. α1‐Antitrypsin (AAT) deficiency and ANCA‐positive systemic vasculitis: genetic and clinical implications
Wang et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients
Kastbom et al. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA* project)
Guerini et al. HLA-G coding region polymorphism is skewed in autistic spectrum disorders
Guay-Bélanger et al. Detection of SQSTM1/P392L post-zygotic mutations in Paget’s disease of bone
Gheissari et al. TRPC6 mutational analysis in iranian children with focal segmental glomerulosclerosis
Muraro et al. Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor Vβ analysis
AU764006B2 (en) Method for disease prognosis based on Fc receptor genotyping
Persson et al. Maternal HLA ib polymorphisms in pregnancy allo-immunization
Vietzen et al. Deletion of the natural killer cell receptor NKG2C encoding KLR2C gene and kidney transplant outcome
EP3551762B1 (fr) Procédé et kit destinés à prédire le risque de thrombose veineuse profonde et d'embolie pulmonaire
de Saint Basile et al. Isolated X-linked thrombocytopenia in two unrelated families is associated with point mutations in the Wiskott-Aldrich syndrome protein gene
Gillett et al. Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis
Gonzalez et al. CD24 as a genetic modifier of disease progression in multiple sclerosis in Argentinean patients
Ikeuchi et al. Polymorphisms in interleukin-4-related genes in patients with minimal change nephrotic syndrome
Kulah et al. Effects of angiotensin-converting enzyme gene polymorphism and serum vitamin D levels on ambulatory blood pressure measurement and left ventricular mass in Turkish hypertensive population
Lee et al. Polymorphsims of CTLA-4 Exon 1+ 49, CTLA-4 Promoter–318 and Fas Promoter–670 in Spondyloarthropathies
Buraczynska et al. Tumor necrosis factor-α gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead